SinoMed's COMETIU Stent System Faces Regulatory Setback in China Despite FDA Breakthrough Designation
核心洞察
China's National Medical Products Administration (搜索) rejected SinoMed's market application for COMETIU (搜索), the world's first self-expanding intracranial drug-coated stent system designed to treat intracranial atherosclerotic stenosis (搜索).
The regulatory rejection caused SinoMed shares to plummet 17.2% following the announcement, despite the device previously receiving FDA Breakthrough Device Designation in August.
COMETIU (搜索) targets patients with intracranial atherosclerosis, a condition where over 70% of cases with intracranial vascular stenosis (搜索) cannot be cured by drugs alone.
Sino Medical Sciences Technology (搜索) faced a significant regulatory setback as China's National Medical Products Administration (搜索) (NMPA) rejected the market application for its innovative COMETIU (搜索) self-expanding intracranial drug-coated stent system, designed to treat intracranial atherosclerotic stenosis (搜索) (ICAS). The rejection sent SinoMed shares tumbling 17.2% to CNY20.86 per share in Shanghai trading.
Regulatory Rejection Impact
SinoMed's unit Sinomed Neurovita Technology (搜索) received notification from the NMPA that the market application for COMETIU (搜索) was not approved, according to the company's announcement. The Tianjin-based firm did not disclose the specific reasons for the initial rejection but stated it would continue discussions with the NMPA's Center for Medical Device Evaluation to advance the registration process in China.
The market reaction was swift and severe, with shares falling 9.4% the day before the announcement and an additional 17.2% following the news. SinoMed scheduled an investor meeting on the Shanghai Stock Exchange's online roadshow platform, with Chairman and General Manager Sun Jianhua set to address questions about the stent system's rejection.
Revolutionary Device for Unmet Medical Need
COMETIU (搜索) represents a significant medical innovation as the world's first therapeutic device specifically designed for ICAS. The device addresses a critical unmet medical need, as over 70% of patients with intracranial vascular stenosis (搜索) cannot be cured by drugs alone, according to SinoMed.
The stent system works by expanding the lumen diameter of patients' intracranial blood vessels (搜索) to improve cerebral ischemia (搜索). This mechanism can shorten the time needed for surgeries while reducing corresponding surgical risks, potentially benefiting millions of stroke (搜索) patients worldwide.
FDA Recognition Contrasts with Chinese Rejection
The Chinese regulatory rejection stands in stark contrast to the device's reception in the United States. The FDA granted COMETIU (搜索) Breakthrough Device Designation on August 4, recognizing it as an innovative medical device that addresses unmet medical needs. This designation provides SinoMed with preferential services, including review priority for product development and clinical trials, reviewer support, and product-launching assistance.
The FDA's Breakthrough Device Designation is reserved for devices that are original with no currently approved products of similar efficacy or alternative solutions, or those with prominent advantages in clinical uses compared to existing treatments. The designation has authorized COMETIU (搜索) for pivotal confirmatory clinical trials in the United States and allows for initial marketing through the FDA's Premarket Approval process.
Global Commercialization Strategy
Despite the setback in China, SinoMed emphasized its commitment to advancing COMETIU (搜索)'s global commercialization. The company noted that securing the FDA's Breakthrough Device Designation would strongly facilitate positioning of its innovative neurological intervention products worldwide and significantly improve its global brand recognition.
The FDA recognition had previously driven significant investor enthusiasm, with SinoMed shares surging 20% to CNY17.03 per share in August following the Breakthrough Device Designation announcement, reaching a new high since November 2020.
Broader Product Portfolio Success
SinoMed's regulatory challenges with COMETIU (搜索) come amid other recent successes in its product development pipeline. The company's HT Supreme™ Drug Coated Coronary Stent System received FDA conditional approval on July 25, becoming China's first domestically developed coronary stent product to receive such approval from the US regulator.
This broader portfolio of innovative medical devices positions SinoMed as a significant player in the interventional medical device market, despite the current regulatory hurdles facing COMETIU (搜索) in its home market.